Clinical Radiology
Volume 64, Issue 1 , Pages 52-63 , January 2009

Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study

  • S.J. Price

      Affiliations

    • Academic Neurosurgery Unit, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • Corresponding Author InformationGuarantor and correspondent: S.J. Price, Academic Neurosurgery Unit, Box 167, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. Tel.: +44 1223 336933; fax: +44 1223 216926.
    • ,
  • T.D. Fryer

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • M.C. Cleij

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • A.F. Dean

      Affiliations

    • Department of Histopathology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • J. Joseph

      Affiliations

    • Department of Histopathology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • R. Salvador

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • Fundacio Sant Joan de Deu, Barcelona, Spain
    • ,
  • D.D. Wang

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • P.J. Hutchinson

      Affiliations

    • Academic Neurosurgery Unit, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • J.C. Clark

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • N.G. Burnet

      Affiliations

    • University Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • J.D. Pickard

      Affiliations

    • Academic Neurosurgery Unit, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • F.I. Aigbirhio

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • ,
  • J.H. Gillard

      Affiliations

    • Wolfson Brain Imaging Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
    • University Department of Radiology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Received 30 July 2007 ,Revised 14 January 2008 ,Accepted 24 January 2008.

References 

  1. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316
  2. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318
  3. Goethals P, Lameire N, van Eijkeren M, et al. [Methyl-carbon-11] thymidine for in vivo measurement of cell proliferation. J Nucl Med. 1996;37:1048
  4. Shields AF, Graham MM, Kozawa SM, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992;33:581
  5. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043
  6. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808
  7. Grierson JR, Schwartz JL, Muzi M, et al. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829
  8. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334
  9. Muzi M, Mankoff DA, Grierson JR, et al. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371
  10. Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281
  11. Buchmann I, Neumaier B, Schreckenberger M, et al. [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations – a pilot study. Cancer Biother Radiopharm. 2004;19:436
  12. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-l-thymidine. Clin Cancer Res. 2004;10:1685
  13. Dittmann H, Dohmen BM, Paulsen F, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407
  14. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274
  15. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720
  16. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′- [18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315
  17. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945
  18. Choi SJ, Kim JS, Kim JH, et al. [18F]3-deoxy-3-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653
  19. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-l-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948
  20. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci. 1989;36:964
  21. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000;
  22. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall; 1993;
  23. Hilton DA, Love S, Barber R, et al. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery. 1998;42:724
  24. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer. 1992;66:373
  25. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery. 1994;34:674
  26. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 1993;52:609
  27. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol. 1989;115:179
  28. Karamitopoulou E, Perentes E, Diamantis I, et al. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol (Berl). 1994;87:47
  29. Raghavan R, Steart PV, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol. 1990;16:123
  30. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986;10:611
  31. Burnet NG, Lynch AG, Jefferies SJ, et al. High-grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol. 2007;85:371
  32. Schroder R, Feisel KD, Ernestus RI. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. J Neurooncol. 2002;56:127
  33. Haapasalo HK, Sallinen PK, Helen PT, et al. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms. J Pathol. 1993;171:207
  34. Torp SH, Helseth E, Dalen A, et al. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien). 1992;117:182
  35. Wakimoto H, Aoyagi M, Nakayama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996;77:373
  36. Bouvier-Labit C, Chinot O, Ochi C, et al. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998;24:381
  37. Litofsky NS, Mix TC, Baker SP, et al. Ki-67 (clone MIB-1) proliferation index in recurrent glial neoplasms: no prognostic significance. Surg Neurol. 1998;50:579
  38. Pigott TJ, Lowe JS, Palmer J. Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg. 1991;5:61
  39. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47
  40. Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg. 1995;82:445
  41. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189
  42. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;43:1667
  43. Kim S, Chung JK, Im SH, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:52
  44. Kuwert T, Probst-Cousin S, Woesler B, et al. Iodine-123-alpha-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med. 1997;38:1551
  45. Pirotte B, Goldman S, Salzberg S, et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg. 2003;38:146
  46. Pirotte B, Goldman S, Massager N, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004;101:476
  47. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746
  48. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology. 1993;186:45
  49. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602
  50. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525
  51. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431
  52. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169
  53. Mosskin M, Bergstrom M, Collins VP, et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol. 1986;369(Suppl.):157
  54. Mosskin M, Ericson K, Hindmarsh T, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989;30:225
  55. Giese A, Loo MA, Tran N, et al. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67:275
  56. Kaczarek E, Zapf S, Bouterfa H, et al. Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Dev Neurosci. 1999;17:625
  57. Yang YJ, Ryu JS, Kim SY, et al. Use of 3′-deoxy-3′-[(18)F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412
  58. Pio B, Park C, Pietras R, et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36

PII: S0009-9260(08)00302-4

doi: 10.1016/j.crad.2008.01.016

Clinical Radiology
Volume 64, Issue 1 , Pages 52-63 , January 2009

Article Tools

* Image Usage & Resolution